[go: up one dir, main page]

BR112012019459A2 - identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. - Google Patents

identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.

Info

Publication number
BR112012019459A2
BR112012019459A2 BR112012019459A BR112012019459A BR112012019459A2 BR 112012019459 A2 BR112012019459 A2 BR 112012019459A2 BR 112012019459 A BR112012019459 A BR 112012019459A BR 112012019459 A BR112012019459 A BR 112012019459A BR 112012019459 A2 BR112012019459 A2 BR 112012019459A2
Authority
BR
Brazil
Prior art keywords
tor kinase
sensitivity
identification
kinase inhibitors
predictive biomarker
Prior art date
Application number
BR112012019459A
Other languages
English (en)
Inventor
Chopra Rajesh
Sankar Sabita
Xu Shuichan
Xu Weiming
Ning Yuhong
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44355759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012019459(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of BR112012019459A2 publication Critical patent/BR112012019459A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. trata-sede métodos aqui fornecidos para tratar e/ou previnir um câncer ou uma síndrome tumoral em um paciente, que compreendem administrar uma quantidade eficaz de um inibidor de tor quinase a um paciente que tem câncer ou uma síndrome tumoral, caracterizado por um gene ou perda de proteína ou mutação de lkb1 e/ou ampk.
BR112012019459A 2010-02-03 2011-02-03 identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. BR112012019459A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30115010P 2010-02-03 2010-02-03
US36298210P 2010-07-09 2010-07-09
PCT/US2011/023524 WO2011097333A1 (en) 2010-02-03 2011-02-03 Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112012019459A2 true BR112012019459A2 (pt) 2017-10-17

Family

ID=44355759

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019459A BR112012019459A2 (pt) 2010-02-03 2011-02-03 identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.

Country Status (24)

Country Link
US (1) US9555033B2 (pt)
EP (2) EP2992878A1 (pt)
JP (1) JP6114554B2 (pt)
KR (2) KR20120123513A (pt)
CN (1) CN102821767A (pt)
AR (1) AR080643A1 (pt)
AU (1) AU2011212927B2 (pt)
BR (1) BR112012019459A2 (pt)
CA (1) CA2788678C (pt)
CR (1) CR20120406A (pt)
EC (1) ECSP12012080A (pt)
ES (1) ES2670659T3 (pt)
HK (1) HK1221642A1 (pt)
IL (1) IL221282A (pt)
MX (1) MX2012009030A (pt)
NI (1) NI201200128A (pt)
NZ (1) NZ601581A (pt)
PH (2) PH12012501581A1 (pt)
RU (1) RU2565034C2 (pt)
SG (1) SG183155A1 (pt)
TW (1) TWI578989B (pt)
UA (1) UA110697C2 (pt)
WO (1) WO2011097333A1 (pt)
ZA (1) ZA201305379B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CA2843887A1 (en) * 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
BR112014009755B1 (pt) * 2011-10-19 2022-09-13 Signal Pharmaceuticals, Llc Tratamento de câncer com inibidores de quinase tor
BR112014013332B1 (pt) 2011-12-02 2022-09-06 Signal Pharmaceuticals, Llc Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
CA2860665A1 (en) * 2012-01-05 2013-07-11 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
BR112014020786A2 (pt) * 2012-02-24 2020-10-27 Signal Pharmaceuticals, Llc método para tratamento de câncer de pulmão, método para alcançar um critério de avaliação de resposta em tumores sólidos, método para aumento da sobrevivência
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
NZ630467A (en) 2013-01-16 2017-02-24 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
JP2016516815A (ja) 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オンに関する医薬製剤、プロセス、固形形態、及び使用方法
NZ631082A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Methods for treating cancer using tor kinase inhibitor combination therapy
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治療癌症的包括tor激酶抑制劑和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的組合療法
TWI604843B (zh) 2013-04-17 2017-11-11 標誌製藥公司 藉二氫吡并吡治療癌症
KR102221029B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
US9604939B2 (en) 2013-05-29 2017-03-28 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use
KR101602532B1 (ko) 2013-08-29 2016-03-11 경북대학교 산학협력단 위암의 재발 가능성 예측을 위한 정보제공 방법
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
KR20170024120A (ko) 2014-07-14 2017-03-06 시그날 파마소티칼 엘엘씨 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
KR101720046B1 (ko) * 2014-09-26 2017-03-29 서울대학교산학협력단 광역학 치료용 자기조립형 약학 조성물
KR101765335B1 (ko) * 2014-09-26 2017-08-22 서울대학교산학협력단 암 세포 조영용 ｍｒｉ 조영제 조성물
KR102708936B1 (ko) 2015-11-20 2024-09-25 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 프로테아제 1 억제제로서의 퓨리논
LT3558997T (lt) 2016-12-20 2021-04-26 Astrazeneca Ab Aminotriazolopiridino junginiai ir jų naudojimas vėžio gydymui
KR102795129B1 (ko) 2017-06-22 2025-04-15 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
RU2646513C1 (ru) * 2017-08-30 2018-03-05 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного рака легкого iiв-iiiа стадии
CN109298102B (zh) * 2018-12-03 2021-09-21 瑞德肝脏疾病研究(上海)有限公司 一种药物肺部代谢特征的体外评价方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW274550B (pt) * 1992-09-26 1996-04-21 Hoechst Ag
WO1999028459A1 (en) 1997-11-27 1999-06-10 Chugai Research Institute For Molecular Medicine, Inc. Examination method, examination reagent and remedy for diseases caused by variation in lkb1 gene
EP1186232A4 (en) 1999-05-31 2004-11-10 Chugai Pharmaceutical Co Ltd 'KNOCKOUT' ANIMALS LACKING THE LKB1 GENE
PE20030968A1 (es) 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
EA013811B1 (ru) 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
DK1651673T3 (da) 2003-07-17 2008-08-18 Univ Dundee Fremgangsmåder til anvendelse af et LKB1/STRAD/MO25-kompleks
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
US20080194019A1 (en) 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1796467A4 (en) 2004-09-24 2009-07-01 Janssen Pharmaceutica Nv INHIBITORS IMIDAZO {4,5-B} PYRAZINONE PROTEIN KINASES
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
AU2005316668B2 (en) * 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
AU2006217742A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, HYDR zonomethyl and 5-membered heterocylic compounds which act as MTOR inhibitors and their use as anti cancer agents
KR20070113252A (ko) 2005-02-25 2007-11-28 쿠도스 파마슈티칼스 리미티드 2,4-디아미노-피리도피리미딘 유도체 및 이의 ｍＴＯＲ억제제로서의 용도
CN101395155A (zh) 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
EP1931670B1 (en) 2005-10-07 2012-09-12 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k
WO2007044729A2 (en) 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
BRPI0618622A2 (pt) 2005-11-17 2011-09-06 Osi Pharm Inc composto, composição, e, uso de um composto
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
AU2007204208A1 (en) 2006-01-11 2007-07-19 Astrazeneca Ab Morpholino pyrimidine derivatives and their use in therapy
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
UA95799C2 (en) 2006-04-26 2011-09-12 Ф. Хоффманн-Ля Рош Аг Pharmaceutical compounds
US20090076009A1 (en) 2006-05-03 2009-03-19 Arnould Jean-Claude Retired Thiazole derivatives and their use as anti-tumour agents
JP2009535388A (ja) 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ ピラゾール誘導体、及びそのｐｉ３ｋ阻害薬としての使用
CN101448827A (zh) 2006-05-22 2009-06-03 阿斯利康(瑞典)有限公司 吲哚衍生物
WO2008023161A1 (en) 2006-08-23 2008-02-28 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032077A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
US20090325954A1 (en) 2006-09-14 2009-12-31 Sam Butterworth 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20100022534A1 (en) 2006-09-14 2010-01-28 Astrazeneca 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032027A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
JP2010503649A (ja) 2006-09-14 2010-02-04 アストラゼネカ アクチボラグ ピリミジン誘導体
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CN101563340A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
CN101679432B (zh) * 2006-10-19 2015-04-22 西格诺药品有限公司 杂芳基化合物、其组合物及其作为蛋白激酶抑制剂的用途
ZA200902382B (en) 2006-10-19 2010-08-25 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
EP2094700B1 (en) 2006-11-20 2014-04-02 Novartis AG Crystalline monotosylate salt of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
US20080234262A1 (en) 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
JP2010532756A (ja) * 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
AU2008273891B2 (en) 2007-07-09 2012-01-12 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
CN101801962A (zh) 2007-07-09 2010-08-11 阿斯利康(瑞典)有限公司 用于治疗增殖疾病的三取代嘧啶衍生物
CN101801963A (zh) 2007-07-09 2010-08-11 阿斯利康(瑞典)有限公司 用于治疗增殖性疾病的三取代的嘧啶衍生物
US20100261723A1 (en) 2007-07-09 2010-10-14 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
EA201000484A1 (ru) 2007-10-16 2010-12-30 ВАЙЕТ ЭлЭлСи Тиенопиримидиновые и пиразолопиримидиновые соединения и их применение в качестве ингибиторов киназы mtor и киназы pi3
EP2252296A1 (en) 2008-01-15 2010-11-24 Wyeth LLC 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US20110091574A1 (en) 2008-02-15 2011-04-21 Catholic Healthcare West Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox2 inhibitor
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
AU2010292102B2 (en) * 2009-09-14 2015-04-09 Gilead Sciences, Inc. Modulators of Toll-like receptors
CN102762568A (zh) 2009-12-23 2012-10-31 伊兰药品公司 作为polo样激酶的抑制剂的蝶啶酮
US20110318336A1 (en) 2010-03-29 2011-12-29 George Mason Intellectual Properties, Inc. Identification and Treatment of Aggressive Lung Cancer Tumors

Also Published As

Publication number Publication date
CN102821767A (zh) 2012-12-12
KR101942212B1 (ko) 2019-01-24
RU2012137279A (ru) 2014-03-10
EP2531194A4 (en) 2013-09-25
PH12020500203A1 (en) 2021-03-15
CA2788678A1 (en) 2011-08-11
EP2531194B1 (en) 2018-04-18
WO2011097333A1 (en) 2011-08-11
EP2531194A1 (en) 2012-12-12
PH12012501581A1 (en) 2012-10-22
CA2788678C (en) 2019-02-26
IL221282A0 (en) 2012-10-31
CR20120406A (es) 2012-10-31
JP2013518890A (ja) 2013-05-23
ECSP12012080A (es) 2012-09-28
JP6114554B2 (ja) 2017-04-12
KR20170116201A (ko) 2017-10-18
NI201200128A (es) 2013-01-18
ZA201305379B (en) 2015-08-26
AU2011212927B2 (en) 2014-10-09
EP2992878A1 (en) 2016-03-09
IL221282A (en) 2016-12-29
HK1221642A1 (en) 2017-06-09
TWI578989B (zh) 2017-04-21
MX2012009030A (es) 2012-09-12
KR20120123513A (ko) 2012-11-08
SG183155A1 (en) 2012-09-27
AU2011212927A1 (en) 2012-08-23
ES2670659T3 (es) 2018-05-31
AR080643A1 (es) 2012-04-25
RU2565034C2 (ru) 2015-10-10
UA110697C2 (uk) 2016-02-10
NZ601581A (en) 2014-03-28
US20110257167A1 (en) 2011-10-20
US9555033B2 (en) 2017-01-31
TW201130846A (en) 2011-09-16

Similar Documents

Publication Publication Date Title
BR112012019459A2 (pt) identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
UA118248C2 (uk) Інгібітори глюкозилцерамідсинтази
EA201590554A1 (ru) Ингибиторы глюкозилцерамид-синтазы
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
BR112014030750A2 (pt) Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
CR20120451A (es) Compuestos para la inhibición de inmunoproteasomas
EA201491701A1 (ru) Лечение рака ингибиторами tor киназы
MX2016007066A (es) Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
BR112015012507A2 (pt) marcadores de diagnóstico para tratar distúrbios de proliferação celular com inibidores da telomerase
BR112015020667A2 (pt) método de preparar inibidores de glucosilceramida sintase
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
BR112015004653A2 (pt) método diagnóstico e terapêutico de câncer de moléculas alvo expressas em células-tronco cancerígenas
BR112013033836A2 (pt) terapia de combinação
BR112014004762A2 (pt) métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula
MX352296B (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
TN2013000368A1 (en) Glucosylceramide synthase inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2500 DE 04-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]